Gilteritinib is developed and produced in which country?

Gilitinib is an oral FLT3 inhibitor, mainly used to treat relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutations. This targeted drug was developed by Astellas Pharma, a famous Japanese pharmaceutical company. It is one of the few effective targeted therapies in the world for FLT3 mutated AML. Its trade name is Xospata, which has been approved for marketing in many countries and is used to improve patient prognosis and survival.

Astellas Pharmaceuticals is a large multinational pharmaceutical company headquartered in Tokyo, Japan, with a profound R&D foundation in the fields of anti-tumor drugs and immunotherapy. The R&D work of giritinib was mainly promoted by the company's R&D teams in Japan and the United States, combined with cutting-edge molecular targeting technology, and finally launched this new drug for the precise treatment of AML patients. Giritinib was first approved by the FDA in the United States in 2018, and was subsequently approved in the European Union, Japan and other places.

In China, giritinib has been approved by the State Food and Drug Administration for the treatment of relapsed or refractory AML adult patients with FLT3 mutations. However, the drug is currently not included in the national medical insurance catalog and the price is relatively high. Domestic purchasing channels may be limited, and some patients choose to obtain drugs through overseas medical channels. In addition to the original version, there are also generic drugs produced by Lao pharmaceutical factories on the market. The price is significantly lower than the original version and the economic burden is smaller.

In general, giritinib, as a targeted drug developed by Japan's Astellas, has been widely recognized and used around the world. It represents an important breakthrough in precision medicine in the field of hematological tumor treatment. However, due to price and medical insurance coverage restrictions, domestic patients still face certain challenges in using it. They need to make reasonable choices based on doctor's advice, financial ability and drug channels.

Reference materials:https://www.xospata.com/